Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atrocoxib-P
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atrocoxib-P is an oral fixed-dose combination tablet developed and marketed by Atro Pharma, a pharmaceutical company based in New Delhi, India. It contains etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor, and paracetamol (acetaminophen), an analgesic and antipyretic. The medication is indicated for the symptomatic relief of moderate pain and joint swelling associated with various inflammatory conditions, including osteoarthritis, rheumatoid arthritis, and acute gouty arthritis. By selectively inhibiting the COX-2 enzyme, the etoricoxib component reduces the production of pro-inflammatory prostaglandins while minimizing the gastrointestinal side effects typically associated with non-selective NSAIDs. Paracetamol provides complementary analgesic effects, making the combination effective for managing acute and chronic musculoskeletal pain.
- Brand names
- Atrocoxib-P
- Other names
- Atrocoxib P
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)Hb (Hemoglobin)PTGES3NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Atrocoxib-P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atrocoxib-P.